Pharmaco-EEG of Antipsychotic Treatment Response: a Systematic Review

Overview

Journal Schizophrenia (Heidelb)

Date 2023 Dec 9

PMID 38071394

Authors

Marco De Pieri

Vincent Rochas

Michel Sabe

Cristoph Michel

Stefan Kaiser

Affiliations

Soon will be listed here.

Abstract

Response to antipsychotic medications (AP) is subjected to a wide and unpredictable variability and efforts were directed to discover predictive biomarkers to personalize treatment. Electroencephalography abnormalities in subjects with schizophrenia are well established, as well as a pattern of EEG changes induced by APs. The aim of this review is to provide a synthesis of the EEG features that are related to AP efficacy, including both pre-treatment signatures and changes induced by APs during treatment. A systematic review of English articles using PubMed, PsychINFO and the Cochrane database of systematic reviews was undertaken until july 2023. Additional studies were added by hand search. Studies having as an endpoint the relationship between AP-related clinical improvement and electroencephalographic features were included. Heterogeneity prevented a quantitative synthesis. Out of 1232 records screened, 22 studies were included in a final qualitative synthesis. Included studies evaluated resting-state and task-related power spectra, functional connectivity, microstates and epileptic abnormalities. At pre-treatment resting-state EEG, the most relevant predictors of a poor response were a change in theta power compared to healthy control, a high alpha power and connectivity, and diminished beta power. Considering EEG during treatment, an increased theta power, a reduced beta-band activity, an increased alpha activity, a decreased coherence in theta, alpha and beta-band were related to a favorable outcome. EEG is promising as a method to create a predictive biomarker for response to APs; further investigations are warranted to harmonize and generalize the contradictory results of reviewed studies.

Citing Articles

Reduced temporal variability of cortical excitation/inhibition ratio in schizophrenia.

Racz F, Farkas K, Becske M, Molnar H, Fodor Z, Mukli P Schizophrenia (Heidelb). 2025; 11(1):20.

PMID: 39966406 PMC: 11836122. DOI: 10.1038/s41537-025-00568-3.

Microstate D as a Biomarker in Schizophrenia: Insights from Brain State Transitions.

Yao R, Song M, Shi L, Pei Y, Li H, Tan S Brain Sci. 2024; 14(10).

PMID: 39451999 PMC: 11505886. DOI: 10.3390/brainsci14100985.

EEG Techniques with Brain Activity Localization, Specifically LORETA, and Its Applicability in Monitoring Schizophrenia.

Zeltser A, Ochneva A, Riabinina D, Zakurazhnaya V, Tsurina A, Golubeva E J Clin Med. 2024; 13(17).

PMID: 39274319 PMC: 11395834. DOI: 10.3390/jcm13175108.

Prospects of Electrocorticography in Neuropharmacological Studies in Small Laboratory Animals.

Sysoev Y, Okovityi S Brain Sci. 2024; 14(8).

PMID: 39199466 PMC: 11353129. DOI: 10.3390/brainsci14080772.

Human neuroimaging and antipsychotic neurobiology at millisecond temporal resolution.

Eisenberg D, Berman K Neuropsychopharmacology. 2024; 50(1):306-307.

PMID: 39060437 PMC: 11525651. DOI: 10.1038/s41386-024-01933-z.

References

Mucci A, Volpe U, Merlotti E, Bucci P, Galderisi S . Pharmaco-EEG in psychiatry. Clin EEG Neurosci. 2006; 37(2):81-98. DOI: 10.1177/155005940603700206. View

Perrottelli A, Giordano G, Brando F, Giuliani L, Mucci A . EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review. Front Psychiatry. 2021; 12:653642. PMC: 8129021. DOI: 10.3389/fpsyt.2021.653642. View

Koukkou M, Angst J, Zimmer D . Paroxysmal EEG activity and psychopathology during the treatment with clozapine. Pharmakopsychiatr Neuropsychopharmakol. 1979; 12(2):173-83. DOI: 10.1055/s-0028-1094608. View

Mailman R, Murthy V . Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Curr Pharm Des. 2009; 16(5):488-501. PMC: 2958217. DOI: 10.2174/138161210790361461. View

Pillay S, Stoll A, Weiss M, Tohen M, Zarate Jr C, Banov M . EEG abnormalities before clozapine therapy predict a good clinical response to clozapine. Ann Clin Psychiatry. 1996; 8(1):1-5. DOI: 10.3109/10401239609149083. View

Kural M, Duez L, Sejer Hansen V, Larsson P, Rampp S, Schulz R . Criteria for defining interictal epileptiform discharges in EEG: A clinical validation study. Neurology. 2020; 94(20):e2139-e2147. PMC: 7526669. DOI: 10.1212/WNL.0000000000009439. View

Wichniak A, Szafranski T, Wierzbicka A, Waliniowska E, Jernajczyk W . Electroencephalogram slowing, sleepiness and treatment response in patients with schizophrenia during olanzapine treatment. J Psychopharmacol. 2005; 20(1):80-5. DOI: 10.1177/0269881105056657. View

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

Itil T . Qualitative and quantitative EEG findings in schizophrenia. Schizophr Bull. 1977; 3(1):61-79. DOI: 10.1093/schbul/3.1.61. View

10.

Pascual-Marqui R, Lehmann D, Koenig T, Kochi K, Merlo M, Hell D . Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naive, first-episode, productive schizophrenia. Psychiatry Res. 1999; 90(3):169-79. DOI: 10.1016/s0925-4927(99)00013-x. View

11.

Kang U, Par K, Ahn Y, Koo Y, Yoon S, Yi S . Non-linear dynamic analysis of clozapine-induced electroencephalographic changes in schizophrenic patients--a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25(6):1229-39. DOI: 10.1016/s0278-5846(01)00183-x. View

12.

Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P . Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006; 20(5):389-409. DOI: 10.2165/00023210-200620050-00004. View

13.

Mackintosh A, de Bock R, Lim Z, Trulley V, Schmidt A, Borgwardt S . Psychotic disorders, dopaminergic agents and EEG/MEG resting-state functional connectivity: A systematic review. Neurosci Biobehav Rev. 2020; 120:354-371. DOI: 10.1016/j.neubiorev.2020.10.021. View

14.

Khodayari-Rostamabad A, Hasey G, Maccrimmon D, Reilly J, de Bruin H . A pilot study to determine whether machine learning methodologies using pre-treatment electroencephalography can predict the symptomatic response to clozapine therapy. Clin Neurophysiol. 2010; 121(12):1998-2006. DOI: 10.1016/j.clinph.2010.05.009. View

15.

Galderisi S, Maj M, Mucci A, Bucci P, KEMALI D . QEEG alpha 1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. Biol Psychiatry. 1994; 35(6):367-74. DOI: 10.1016/0006-3223(94)90002-7. View

16.

Tislerova B, Brunovsky M, Horacek J, Novak T, Kopecek M, Mohr P . LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia. Neuropsychobiology. 2008; 58(1):1-10. DOI: 10.1159/000154474. View

17.

Knott V, LABELLE A, Jones B, Mahoney C . Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment. Schizophr Res. 2001; 50(1-2):41-53. DOI: 10.1016/s0920-9964(00)00165-1. View

18.

Nikolac Perkovic M, Nedic Erjavec G, Strac D, Uzun S, Kozumplik O, Pivac N . Theranostic Biomarkers for Schizophrenia. Int J Mol Sci. 2017; 18(4). PMC: 5412319. DOI: 10.3390/ijms18040733. View

19.

Ravan M, Hasey G, Reilly J, MacCrimmon D, Khodayari-Rostamabad A . A machine learning approach using auditory odd-ball responses to investigate the effect of Clozapine therapy. Clin Neurophysiol. 2014; 126(4):721-30. DOI: 10.1016/j.clinph.2014.07.017. View

20.

Itil T, Marasa J, Saletu B, Davis S, Mucciardi A . Computerized EEG: predictor of outcome in schizophrenia. J Nerv Ment Dis. 1975; 160(3):118-203. View